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The improvement of bioavailability of honokiol, sustained release of 
honokiol and prolongation of half-time were obtained. The inhibition 
of cell proliferation and induced apoptosis of liposomal honokiol were 
time and dose-dependent in in vitro study. The liposomal honokiol 
inhitbited tumor growth in a dose-dependent manner and the antitu-
mor efﬁcacy of liposomal honokiol can be signiﬁcantly enhanced in 
combination with cisplatin. This combination treatment has shown 
marked suppression in tumor growth, prolonged survival and decreased 
microvessel density compared with either treatment alone.
Conclusions: The in vitro and in vivo antitumor effects of liposomal 
honokiol combined with cisplatin indicated that liposomal honokiol can 
be a potential agent as a new sensitizer of anti- lung cancer drug. 
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Background: Oncolytic adenoviruses kill tumor cells by different 
mechanisms from standard anticancer therapies, and synergistic inter-
actions with conventional treatments have been described. However, 
the molecular mechanisms underlying combination-therapy synergy are 
not fully known. 
Methods: We constructed telomerase-speciﬁc replication-competent 
adenovirus (OBP-301: Telomelysin), in which the human telomerase 
reverse transcriptase (hTERT) promoter regulates viral replication. The 
antitumor effects of OBP-301 infection and ionizing radiation were 
evaluated in vitro by XTT assay. Adenovirus infectivity and intracellu-
lar replication were assessed by real-time quantitative PCR. The effects 
of OBP-301 on DNA-protein kinase (PK) catalytic subunit (DNA-
PKcs) expression and nuclear translocation of Ku70/80 were examined 
by western blotting and immunoﬂuorescence staining, respectively. The 
effect of treatment on growth of subcutaneous human tumors trans-
planted into nu/nu mice was compared. 
Results: Post-radiation infection with OBP-301 induced profound in 
vitro cytotoxicity. The virulence of OBP-301 was more efﬁcient after 
radiation, although radiation did not inﬂuence OBP-301 intracellular 
replication rate. OBP-301 infection reduced DNA-PKcs expression in 
A549 human lung cancer cells even after radiation. Ku70/80 protein 
accumulated in nuclei of A549 cells after ionizing radiation but in the 
cytoplasm after OBP-301 infection. Intratumoral injection of OBP-301 
and localized radiation showed a signiﬁcant therapeutic synergism in 
nu/nu mice xenografted with A549 tumor, but OBP-301 and radiation 
induced only modest inhibition of tumor growth when administered 
alone. 
Conclusions: Ionizing radiation and OBP-301 infection mutually 
sensitize tumor cells by increasing viral infectivity and inhibiting DNA 
repair, respectively. This combination therapy efﬁciently enhanced 
antitumor efﬁcacy both in vitro and in vivo. 
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Genetic immunotherapy using tumor vaccine has been tried more than 
a decade without practical impact on clinics. Among several limitations 
of tumor vaccine, low levels of transferred genes, such as cytokines 
and MHC class molecules, are one of major reasons. We previously 
demonstrated that combination gene therapy with conditionally repli-
cating adenovirus (CRAD: Δ24RGD) and adenovirus-p27 induced the 
higher, more extensive and prolonged expression of p27 in human lung 
cancer xenografts and induced the synergistic tumor regression (Cancer 
Research 2006;66:372). Even though this combination of CRAD and 
ad-p27 showed increased expression, the antitumor effects are still 
locoregional. Since cancer is a systemic disease, local treatment effect 
has a limitation for the cure of cancer. Therefore, we have applied the 
combination of CRAD(Δ24) and ad-cytokines (IL-4, GM-CSF and 
IFNβ) in murine lung cancer model (LLC1). Transduction of LLC1 
with Δ24 induced the replication of Δ24, but replication in LLC1 was 
much weaker than that in human lung cancer cell line (NCI H460). 
However, combined transduction of LLC1 with Δ24 and ad-cytokines 
induced stronger and more prolonged expression of cytokine com-
pared with ad-cytokines only (at least 10 times higher expression). It 
means that mutant E1 produced from Δ24 enables the replication of E1 
deleted replication defective adenovirus(ad-cytokines) in tumor when 
cotransduced with both viruses. We performed the in vivo treatment 
experiment by injecting LLC1 transduced in vitro (tumor vaccine) with 
Δ24 only, ad-cyokines only and Δ24 + ad-cytokine, into mice with pre-
established lung cancer(LLC1). Tumor vaccine of Δ24 and ad-cytokine 
more strongly suppressed the growth of preestablished tumor (LLC1) 
compared with other tumor vaccines (Δ24 only and ad-cytokines only). 
These ﬁndings suggest the potential of new tumor vaccine strategy us-
ing combined transduction of CRAD and ad-cytokines. (This study was 
supported by a grant of the Korea Health 21 R&D project, Ministry of 
Health & Welfare, Republic of Korea, A06-00024600)
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Inhibition of poly(ADP-ribose) polymerase enhances cell death and 
improves tumor growth delay in irradiated lung cancer models
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Purpose: Poly(ADP-ribose) polymerase-1 (PARP-1) is the founding 
member of a family of enzymes that catalyze the addition of ADP-ri-
bose units to proteins that mediate DNA repair pathways. Ionizing ra-
diation induces DNA strand breaks, suggesting that PARP-1 inhibition 
may sensitize tumor cells to radiation. 
Experimental Design: We investigated the combination of PARP-1 in-
hibition with radiation in lung cancer models. ABT-888, a novel potent 
PARP-1 inhibitor, was used to explore the effects of PARP-1 inhibition 
on irradiated tumors and tumor vasculature.
Results: ABT-888 reduced clonogenic survival in H460 lung cancer 
cells, and inhibited DNA repair as shown by enhanced expression 
of DNA strand break marker histone γ-H2AX. Both apoptosis and 
